Filtering by:
FDAFDA Approves Drug Combination for Aggressive Type of Thyroid Cancer
The US Food and Drug Administration (FDA) has approved a combination of 2 targeted drugs to treat people with anaplastic thyroid cancer that has a certain type of gene mutation (BRAF V600E) and cannot be completely removed through surgery.
FDA Approves Consumer Test for Certain BRCA Mutations
The US Food and Drug Administration (FDA) has approved the first direct-to-consumer tests for certain BRCA1 and BRCA2 gene mutations.
FDA Approves Imfinzi (Durvalumab) for Some Lung Cancers
The US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) for people with stage III (3) non-small cell lung cancer who are not able to be treated with surgery to remove their tumor, and whose cancer has not gotten worse after they received chemotherapy along with radiation (chemoradiation).
FDA Approves Erleada (Apalutamide) for Some Prostate Cancers
The US Food and Drug Administration (FDA) has approved Erleada (apalutamide) to treat men with non-metastatic castration-resistant prostate cancer.
FDA Approves Lutathera for Certain Digestive Tract Cancers
The US Food and Drug Administration (FDA) has approved Lutathera (lutetium Lu 177 dotatate) to treat people with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
FDA Approves First Drug Specifically for BRCA-mutated Breast Cancer
The US Food and Drug Administration (FDA) has for the first time approved a treatment specifically for a type of breast cancer caused by a mutated BRCA gene: Lynparza (olaparib).
New Cancer Drug Approvals From 2017
In 2017, the FDA approved several new drug treatments for different cancer types that American Cancer Society editors believe will make a significant difference.
FDA Expands Approval for Sutent (Sunitinib) After Kidney Cancer Surgery
The US Food and Drug Administration (FDA) has approved Sutent (sunitinib) to treat adults who are at high risk of kidney cancer returning after they’ve had a nephrectomy, surgical removal of a kidney.